BackMerrimack Pharmaceuticals Overview

Merrimack Pharmaceuticals EBIT

EBIT (Earnings Before Interest and Taxes) analysis for MACK.

Quarterly EBIT

-$669.00K
↓ 49.66% YoY

As of Mar 31, 2024

Annual EBIT (TTM)

-$2.54M
↓ 33.18% YoY

Trailing 12 months ending Mar 31, 2024

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin